Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANKIT N MEHTA

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1295944346
CMS profile
149804
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$263,145.89

303 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $100,667.88 153
Bayer HealthCare Pharmaceuticals Inc. $67,266.39 61
GENZYME CORPORATION $55,825.19 61
Pharmacosmos Therapeutics Inc. $20,739.88 20
Chiesi USA, Inc. $12,195.74 3
GlaxoSmithKline, LLC. $3,918.71 2
Lilly USA, LLC $2,400.00 1
Novo Nordisk Inc $105.49 1
Alnylam Pharmaceuticals Inc. $26.61 1

Page 3 of 7; records 101–150 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANKIT N MEHTA

NPI 1295944346 · CMS profile ID 149804

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 7; records 101–150 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295944346?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANKIT N MEHTA, NPI 1295944346, CMS profile ID 149804. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295944346?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ANKIT N MEHTA, NPI 1295944346, CMS profile ID 149804. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295944346?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ANKIT N MEHTA, NPI 1295944346, CMS profile ID 149804, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 303 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1295944346?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

303 matching records · $263,145.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 303 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 303.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $23.0509/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914999199 CMS
AstraZeneca Pharmaceuticals LP $296.2009/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915101385 CMS
AstraZeneca Pharmaceuticals LP $39.5609/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915248755 CMS
AstraZeneca Pharmaceuticals LP $16.3109/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915607869 CMS
AstraZeneca Pharmaceuticals LP $114.4509/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915625469 CMS
AstraZeneca Pharmaceuticals LP $123.1009/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914757411 CMS
AstraZeneca Pharmaceuticals LP $13.2609/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914804555 CMS
AstraZeneca Pharmaceuticals LP $38.7509/07/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915721089 CMS
AstraZeneca Pharmaceuticals LP $36.8809/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915879019 CMS
Pharmacosmos Therapeutics Inc. $2,250.0009/06/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959144369 CMS
GENZYME CORPORATION $34.4708/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964585 CMS
GlaxoSmithKline, LLC. $18.7108/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944918183 CMS
Pharmacosmos Therapeutics Inc. $114.7708/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959144364 CMS
GENZYME CORPORATION $24.2508/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964619 CMS
GENZYME CORPORATION $27.0008/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964621 CMS
GENZYME CORPORATION $121.6408/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964625 CMS
GENZYME CORPORATION $5,628.0008/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964627 CMS
GENZYME CORPORATION $255.7008/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964629 CMS
GENZYME CORPORATION $24.9908/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964631 CMS
GENZYME CORPORATION $144.1908/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964633 CMS
GENZYME CORPORATION $177.8008/23/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964635 CMS
AstraZeneca Pharmaceuticals LP $1,556.0008/15/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915336103 CMS
AstraZeneca Pharmaceuticals LP $1,150.0008/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915845427 CMS
AstraZeneca Pharmaceuticals LP $23.1308/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915445325 CMS
Pharmacosmos Therapeutics Inc. $10,174.7708/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959144359 CMS
AstraZeneca Pharmaceuticals LP $1,150.0008/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914749497 CMS
AstraZeneca Pharmaceuticals LP $1,950.0008/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915834803 CMS
AstraZeneca Pharmaceuticals LP $27.5008/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915210013 CMS
AstraZeneca Pharmaceuticals LP $14.6308/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914878281 CMS
AstraZeneca Pharmaceuticals LP $38.7508/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915661805 CMS
GENZYME CORPORATION $18.7607/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964569 CMS
GENZYME CORPORATION $5,092.0007/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964571 CMS
GENZYME CORPORATION $472.6007/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964573 CMS
GENZYME CORPORATION $16.2807/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964575 CMS
GENZYME CORPORATION $28.1307/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964577 CMS
GENZYME CORPORATION $27.0007/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964579 CMS
GENZYME CORPORATION $395.8807/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964587 CMS
AstraZeneca Pharmaceuticals LP $1,150.0007/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914663129 CMS
AstraZeneca Pharmaceuticals LP $1,950.0007/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915550613 CMS
AstraZeneca Pharmaceuticals LP $1,550.0007/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915856445 CMS
AstraZeneca Pharmaceuticals LP $22.5007/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915776473 CMS
AstraZeneca Pharmaceuticals LP $1,150.0007/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915758007 CMS
Alnylam Pharmaceuticals Inc. $26.6107/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926085223 CMS
AstraZeneca Pharmaceuticals LP $18.5207/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914860187 CMS
AstraZeneca Pharmaceuticals LP $42.5007/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915295651 CMS
AstraZeneca Pharmaceuticals LP $1,950.0007/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915407323 CMS
AstraZeneca Pharmaceuticals LP $25.0007/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915449337 CMS
AstraZeneca Pharmaceuticals LP $39.6007/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915849515 CMS
GENZYME CORPORATION $83.9007/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964597 CMS
GENZYME CORPORATION $5,092.0007/13/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938964599 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $26,761.67 41
PY2020 $25,311.29 24
PY2021 $69,717.51 64
PY2022 $263,145.89 303
PY2023 $297,405.61 335
PY2024 $223,842.80 244
PY2025 $216,855.33 176

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $663,695.39 33
PY2024 Principal investigator $509,022.94 88
PY2023 Principal investigator $402,351.40 169
PY2022 Principal investigator $122,375.40 9
PY2021 Principal investigator $77,917.11 87
PY2020 Principal investigator $121,712.00 10
PY2019 Principal investigator $29,621.50 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $4,265.00 12/15/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119264
Principal investigator 1 Novartis Pharmaceuticals Corporation $403.05 11/15/2025 Non-covered Recipient Entity
SCOTT AND WHITE MEDICAL CENTER
A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated A No dispute reported 06/30/2026 1190305123
Principal investigator 1 GENZYME CORPORATION $10,967.00 11/10/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226119260
Principal investigator 1 SANOFI US SERVICES INC. $14,650.00 10/29/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
Fabry Disease Registry Protocol No dispute reported 06/30/2026 1226119266
Principal investigator 1 GENZYME CORPORATION $9,904.00 10/27/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119249
Principal investigator 1 GENZYME CORPORATION $7,250.00 09/15/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119234
Principal investigator 1 Amicus Therapeutics, Inc. $2,600.00 08/27/2025 Non-covered Recipient Entity
Renal Disease Research Institute LLC
A Study to Evaluate Migalastat in Fabry Subjects with Amenable GLA Variant and Renal Disease No dispute reported 06/30/2026 1252319859
Principal investigator 1 Amicus Therapeutics, Inc. $2,600.00 08/27/2025 Non-covered Recipient Entity
Renal Disease Research Institute LLC
A Study to Evaluate Migalastat in Fabry Subjects with Amenable GLA Variant and Renal Disease No dispute reported 06/30/2026 1252320203
Principal investigator 1 GENZYME CORPORATION $21,110.00 08/25/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
ACT - POC clinical study - CD40L mAb - frexalimab No dispute reported 06/30/2026 1226119239
Principal investigator 1 GENZYME CORPORATION $1,430.00 08/25/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226119245
Principal investigator 1 Amgen Inc. $125,118.00 08/13/2025 Non-covered Recipient Entity
RENAL DISEASE RESEARCH INSTITUTE - LANDRY OFFICE
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246647141
Principal investigator 1 Celgene Corporation $75,459.00 08/07/2025 Non-covered Recipient Entity
Baylor Scott And White Research Institute
A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE) No dispute reported 06/30/2026 1222305790
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $752.78 07/28/2025 Non-covered Recipient Entity
Baylor Scott And White Research Institute
A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE) No dispute reported 06/30/2026 1235998722
Principal investigator 1 SANOFI US SERVICES INC. $20,250.00 07/16/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
Fabry Disease Registry Protocol No dispute reported 06/30/2026 1226119253
Principal investigator 1 GENZYME CORPORATION $6,490.00 07/14/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119232
Principal investigator 1 GENZYME CORPORATION $7,686.00 06/23/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119227
Principal investigator 1 GENZYME CORPORATION $6,261.00 06/09/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226119224
Principal investigator 1 SANOFI US SERVICES INC. $14,750.00 05/14/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
Fabry Disease Registry Protocol No dispute reported 06/30/2026 1226119271
Principal investigator 1 Chiesi USA, Inc. $3,500.00 04/30/2025 Non-covered Recipient Entity
RENAL DISEASE RESEARCH INSTITUTE
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients No dispute reported 06/30/2026 1234400312
Principal investigator 1 Chiesi USA, Inc. $43,977.00 04/30/2025 Non-covered Recipient Entity
RENAL DISEASE RESEARCH INSTITUTE
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients No dispute reported 06/30/2026 1234400316
Principal investigator 1 GENZYME CORPORATION $2,535.00 04/28/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226119217
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,042.70 04/23/2025 Non-covered Recipient Entity
AVICENNA DM CLINICAL RESEARCH
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185538651
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,914.28 04/15/2025 Non-covered Recipient Entity
RENAL DISEASE RESEARCH INSTITUTE
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids i No dispute reported 06/30/2026 1190309954
Principal investigator 1 GENZYME CORPORATION $14,552.00 04/07/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119211
Principal investigator 1 GENZYME CORPORATION $3,315.00 03/17/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy No dispute reported 06/30/2026 1226119207
Principal investigator 1 GENZYME CORPORATION $6,938.00 02/18/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119200
Principal investigator 1 SANOFI US SERVICES INC. $14,575.00 02/14/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
Fabry Disease Registry Protocol No dispute reported 06/30/2026 1226119214
Principal investigator 1 GENZYME CORPORATION $3,333.95 02/10/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119204
Principal investigator 1 Novartis Pharmaceuticals Corporation $45,390.00 01/30/2025 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated A No dispute reported 06/30/2026 1190300191
Principal investigator 1 Novartis Pharmaceuticals Corporation $158,529.79 01/15/2025 Non-covered Recipient Entity
DALLAS NEPHROLOGY ASSOCIATES
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids i No dispute reported 06/30/2026 1190304567
Principal investigator 1 GENZYME CORPORATION $3,934.00 01/13/2025 Non-covered Recipient Entity
Renal Disease Reasearch Institute L
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months No dispute reported 06/30/2026 1226119196
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,242.20 01/08/2025 Non-covered Recipient Entity
RENAL DISEASE RESEARCH INSTITUTE
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185538653
Principal investigator 1 Novartis Pharmaceuticals Corporation $970.64 01/01/2025 Non-covered Recipient Entity
SCOTT AND WHITE MEDICAL CENTER
A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated A No dispute reported 06/30/2026 1190304737